Claims
- 1. A compound of Formula I,
- 2. A compound selected from the group consisting of compounds 3, 5, 6, 10, 12, 23, 26-31, 34, and 35 of FIGS. 1A and 11B, or a salt thereof.
- 3. A compound of claim 2, wherein the compound is compound 3 of FIGS. 1A and 1B.
- 4. A compound of claim 2, wherein the compound is compound 5 of FIGS. 1A and 1B.
- 5. A compound of claim 2, wherein the compound is compound 6 of FIGS. 1A and 1B.
- 6. A compound of claim 2, wherein the compound is compound 10 of FIGS. 1A and 1B.
- 7. A compound of claim 2, wherein the compound is compound 12 of FIGS. 1A and 1B.
- 8. A compound of claim 2, wherein the compound is compound 23 of FIGS. 1A and 1B.
- 9. A compound of claim 2, wherein the compound is compound 34 of FIGS. 1A and 1B.
- 10. A compound of claim 1, wherein the compound is compound 35 of FIG. 1.
- 11. A pharmaceutical formulation comprising the compound of claim 1, and a physiologically acceptable excipient.
- 12. A pharmaceutical formulation comprising the compound of claim 2, and a physiologically acceptable excipient.
- 13. A method of single-photon computed tomography (SPECT) imaging of opioid receptors in a subject, the method comprising:
obtaining a compound of claim 1 and labeling the compound with a radioactive label, administering the labeled compound to the subject; and obtaining scans with a SPECT camera to image the opioid receptors.
- 14. The method of claim 13, wherein the radioactive label is 123I.
- 15. The method of claim 13, wherein the compound is compound 34 in FIGS. 1A and 1B.
- 16. The method of claim 13, wherein the compound is compound 35 in FIGS. 1A and 1B.
- 17. A SPECT imaging reagent comprising 123I-labeled compound 34 or 35 in FIGS. 1A and 1B.
- 18. A method of positron emission tomography (PET) imaging of brain opioid receptors in a subject, the method comprising:
obtaining a compound of claim 1 and labeling the compound with a radioactive label; administering the labeled compound to the subject; and obtaining brain scans with a PET camera to image the opioid receptors.
- 19. The method of claim 18, wherein the radioactive label is 18F.
- 20. The method of claim 18, wherein the compound is compound 3 in FIGS. 1A and 1B.
- 21. The method of claim 18, wherein the compound is compound 10 in FIGS. 1A and 1B.
- 22. A PET imaging reagent comprising 18F-labeled compound 3 or 10 in FIGS. 1A and 1B.
- 23. A method of treating a patient addicted to cocaine, the method comprising administering to the patient an effective amount of a compound of formula I:
- 24. A method of claim 23, wherein R is fluoropropyl; 2-ethoxyethyl; 2-methoxyethyl; 3,3,3-trifluoropropyl; 3-cyanopropyl; thienylmethyl; a Mannich base derivative ketone; an alcohol of a Mannich base derivative ketone; 3-iodoprop-(2E)-enyl; or 3-iodoprop-(2Z)-enyl; or a salt thereof.
- 25. A method of claim 23, wherein the compound is selected from the group consisting of compounds 3, 5, 6, 10, 12, 23, 26-31, 34, and 35 of FIGS. 1A and 1B, or a salt thereof.
- 26. A method of claim 23, wherein the compound is selected from the group consisting of compounds 3, 4, 5, 6, 8, 9, 11, 12, 34, and 35 of FIGS. 1A and 1B, or a salt thereof.
- 27. A method of claim 23, wherein the compound is selected from the group consisting of compounds 3, 9, and 34 of FIGS. 1A and 1B, or a salt thereof
- 28. A method of identifying a drug useful for treating a patient addicted to cocaine, the method comprising identifying a compound having nonselective κ opioid receptor agonist activity and either μ opioid receptor agonist or antagonist activity.
- 29. A method of treating a patient addicted to cocaine, the method comprising administering to the patient an effective amount of a drug identified according to the method of claim 28.
- 30. A method of preparing a pharmaceutical formulation, the method comprising identifying a compound having nonselective κ opioid receptor agonist activity and either 11 opioid receptor agonist or antagonist activity; and combining the compound with a physiologically acceptable excipient to prepare the formulation.
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application claims benefit of priority from U.S. Provisional Patent Application Serial No. 60/312,682, filed on Aug. 15, 2001, which is incorporated herein by reference in its entirety.
STATEMENT AS TO FEDERALLY SPONSORED RESEARCH
[0002] This invention was made with Government support under grant numbers K05-DA00360, U-19-DA11007, and K05-DA00101, awarded by National Institute on Drug Abuse. The Government has certain rights in the invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60312682 |
Aug 2001 |
US |